{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:54:40Z","timestamp":1788990880598,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012462","name":"Office of Academic Affiliations, Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IIR 16-072"],"award-info":[{"award-number":["IIR 16-072"]}],"id":[{"id":"10.13039\/100012462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["14bgia20460366"],"award-info":[{"award-number":["14bgia20460366"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["CIN13-413"],"award-info":[{"award-number":["CIN13-413"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007828"],"award-info":[{"award-number":["T32HL007828"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10557-020-07061-2","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T07:03:36Z","timestamp":1599116616000},"page":"533-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-032X","authenticated-orcid":false,"given":"Akash","family":"Kataruka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Mahtta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Akeroyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi S.","family":"Hira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"issue":"14","key":"7061_CR1","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330.","journal-title":"N Engl J Med"},{"issue":"10117","key":"7061_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219\u201329.","journal-title":"Lancet."},{"issue":"25","key":"7061_CR3","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","volume":"73","author":"SS Anand","year":"2019","unstructured":"Anand SS, Eikelboom JW, Dyal L, et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial. J Am Coll Cardiol. 2019;73(25):3271\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"7061_CR4","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1016\/j.jacc.2019.04.046","volume":"73","author":"A Darmon","year":"2019","unstructured":"Darmon A, Sorbets E, Ducrocq G, et al. Association of multiple enrichment criteria with ischemic and bleeding risks among COMPASS-eligible patients. J Am Coll Cardiol. 2019;73(25):3281\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"7061_CR5","unstructured":"Knuuti J, Wijns W, Saraste A, et al. ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;2019."},{"key":"7061_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ahj.2016.07.020","volume":"181","author":"SS Virani","year":"2016","unstructured":"Virani SS, Akeroyd JM, Ramsey DJ, et al. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: implications for care under the affordable care act. Am Heart J. 2016;181:74\u201382.","journal-title":"Am Heart J"},{"key":"7061_CR7","unstructured":"Centers for Medicare and Medicaid Services. Decision memo for transcatheter aortic valve replacement (TAVR) (CAG-00430N). https:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?NCAId=257. Accessed 28 March 2018."},{"issue":"9","key":"7061_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/eurheartj\/ehx658","volume":"39","author":"A Darmon","year":"2018","unstructured":"Darmon A, Bhatt DL, Elbez Y, et al. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018;39(9):750\u2013757a.","journal-title":"Eur Heart J"},{"issue":"10117","key":"7061_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","volume":"391","author":"SJ Connolly","year":"2018","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205\u201318.","journal-title":"Lancet."},{"key":"7061_CR10","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020.","DOI":"10.1016\/j.jvs.2020.04.470"},{"key":"7061_CR11","doi-asserted-by":"crossref","unstructured":"Vanassche T, Verhamme P, Anand SS, et al. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: an analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiol. 2019;2047487319882154.","DOI":"10.1093\/eurheartj\/ehz745.0116"},{"issue":"8","key":"7061_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1177\/2047487318817910","volume":"26","author":"E Zomer","year":"2019","unstructured":"Zomer E, Si S, Hird TR, et al. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: an Australian healthcare perspective. Eur J Prev Cardiol. 2019;26(8):858\u201368.","journal-title":"Eur J Prev Cardiol"},{"key":"7061_CR13","doi-asserted-by":"crossref","unstructured":"Cowie MR, Lamy A, Levy P, et al. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovasc Res. 2019.","DOI":"10.1093\/cvr\/cvz278"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07061-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T16:41:15Z","timestamp":1630687275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07061-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["7061"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07061-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"21 August 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"AK: supported by T32HL007828 from NHLBI training grant. SSV: supported by research funding from the Department of Veterans Affairs Health Services Research & Development (IIR 16\u2013352,072), World Heart Federation and Tahir and Jooma Family. SSV received honorarium from the American College of Cardiology (Associate Editor for Innovations, ) and serves on the steering committee for the Patient and Provider Assessment of Lipid Management (PALM) registry at the Duke Clinical Research Institute (no financial remuneration). CMB: grant\/research support\u2014all significant (all paid to institution, not individual): Akcea, Amgen, Esperion, Novartis, Regeneron, Sanofi-Synthelabo, NIH, AHA, ADA. Consultant\u2014Abbott Diagnostics, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Corvidia, Denka Seiken, Esperion, Intercept, Matinas BioPharma Inc., Merck, Novartis, Regeneron, Sanofi-Synthelabo. RSH: Consultant\u2014Abbott Vascular Inc., ASAHI Intec. JAS: Consultant \u2013 Janssen. DLB: Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence\/ReachMD (CME steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today\u2019s Intervention), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald\u2019s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda. DM, LAP, DSK and JMA have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}